These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25086399)

  • 21. Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.
    Tada R; Hidaka A; Iwase N; Takahashi S; Yamakita Y; Iwata T; Muto S; Sato E; Takayama N; Honjo E; Kiyono H; Kunisawa J; Aramaki Y
    PLoS One; 2015; 10(10):e0139785. PubMed ID: 26440657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid.
    Chen W; Yan W; Huang L
    Cancer Immunol Immunother; 2008 Apr; 57(4):517-30. PubMed ID: 17724588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endosomal translocation of CpG-oligodeoxynucleotides inhibits DNA-PKcs-dependent IL-10 production in macrophages.
    Yotsumoto S; Saegusa K; Aramaki Y
    J Immunol; 2008 Jan; 180(2):809-16. PubMed ID: 18178819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
    Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
    Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
    Mossman SP; Evans LS; Fang H; Staas J; Tice T; Raychaudhuri S; Grabstein KH; Cheever MA; Johnson ME
    Vaccine; 2005 May; 23(27):3545-54. PubMed ID: 15855013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
    Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
    Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
    Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
    J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.
    Yan W; Huang L
    Int J Pharm; 2009 Feb; 368(1-2):56-62. PubMed ID: 18992312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
    Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
    Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
    Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
    AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects.
    Shariat S; Badiee A; Amir Jalali S; Mansourian M; Alireza Mortazavi S; Reza Jaafari M
    Iran J Basic Med Sci; 2015 May; 18(5):506-13. PubMed ID: 26124938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion.
    Shi R; Hong L; Wu D; Ning X; Chen Y; Lin T; Fan D; Wu K
    Cancer Biol Ther; 2005 Feb; 4(2):218-24. PubMed ID: 15753659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.
    Gholizadeh Z; Tavakkol-Afshari J; Nikpoor AR; Jalali SA; Jaafari MR
    J Cell Mol Med; 2018 Jan; 22(1):558-567. PubMed ID: 28944998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study.
    Nikpoor AR; Jaafari MR; Zamani P; Teymouri M; Gouklani H; Saburi E; Darban SA; Badiee A; Bahramifar A; Fasihi-Ramandi M; Taheri RA
    Int J Pharm; 2019 Aug; 567():118492. PubMed ID: 31271815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel liposomal recombinant lipoimmunogen enhances anti-tumor immunity.
    Shen KY; Liu HY; Li HJ; Wu CC; Liou GG; Chang YC; Leng CH; Liu SJ
    J Control Release; 2016 Jul; 233():57-63. PubMed ID: 27164542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.